

A. Human Mineralocorticoid Receptor ([MR-NR3C2](#)) AS4 aldosterone.pdb [Task for studies](#).

ChemScape MDL  RasMol  (RasMac ) ; MAGE  FireFox application at:  
[htdocsLocal <http://aris.gusc.lv/ChemFiles/BilipidCholine/Membrane/MineraloCorticoidReceptor/NR-A-G-P-R2AA2.htm>](http://aris.gusc.lv/ChemFiles/BilipidCholine/Membrane/MineraloCorticoidReceptor/NR-A-G-P-R2AA2.htm)

B. RSU Aris Kaksis 2025 molecular tutorials: solution MinerCorticoidAldosteronAnswer.doc.

- 1) 2AA2.pdb, 2005 The Journal of Biological Chemistry, Departments of Gene Expression and Protein Biochemistry  
 2) [4FNE.pdb](#); [PLoS Genet.](#) 2012;8(11)

3. Which steroid molecule exhibit potent mineralocorticoid receptorMR activation?.....

1. ....aldosterone .....

4. What four activation types induce **MR** weak, antihypertensive, binding selectivity over?

1. **MR** weak .....progesterone 2. antihypertensive spironolactone.....

3. binding selectivity.....cortisol over 4. cortisone.....

5. What four Physiological roles in the **HOMEOSTASIS regulation** in Human body?

1. ... plays a physiological role in the **HOMEOSTASIS regulation** of water and **electrolyte** .....


2. ... primarily sodium **Na<sup>+</sup>** and potassium **K<sup>+</sup>** levels regulation .

3. ... effects on the **colon**.....and **kidney**..... in the **distal nephron**.....

4. largest influence on vascular blood pressure.....

6. Put in Aldosterone

hydrocarbon chains C21  
 structural formula having two carbonyl **O=C<**, one aldehyde **O=CH-**, and two hydroxyl oxygen atoms **-OH!**



Show carbon –C– cyclic structures **A,B,C,D**, one double bond >C4=C5< and one –CH<sub>3</sub>!

7. What subgroups super families of the **oxosteroid nuclear receptors** (NR) includes?.....

1. ....Androgen receptor (AR), .....

2. ....Glucocorticoid receptor (GR), .....

3. ....progesterone receptor (PR).....

8. What Nuclear receptor Complexes contains as three major functional **Domains**?.....

1. **N-terminal** domen ..... variable receptor **activations domen** ... DNA binding;

2. **DNA Binding Domain (DBD)** is receptor **central** part , and .....

3. **C-terminal** signaling molecule - **Ligand Binding Domain (LBD)**. .....

9. What helices and beta structure **aldosterone** contacting residues bound in a fully enclosed pocket? ..... helices **H3,H4,H5,H6, H7,H9&H11**,and 4  $\beta$ -coupled **strands** .....

10. What one of three amino acid side chain the hydrogen bond—O—H...O=C< and two amino acids **backbone carbonyls** >C=O: bound to **AS4** in 1AA2Marz.pdb?

Thr945....-O-H... O=C<sub>AS4</sub>.22C-O-H...O=C<Phe941.... un AS4.-O-H...O=C<Cys942....

11. What type secondary structures dose contains the **LBD** androgen receptor **MR 2AA2.pdb**?

**4-  $\beta$ -strands, two  $\beta$ -sheets, 11 Alpha-helices**.....

12. How many **alpha helices** has **LBD** polypeptide molecule **2AA2.pdb**?**11 Alpha-helices**.....

13. How many **beta structures**: sheets and how many **beta strands** constitute **LBD** molecule **2AA2.pdb**? **4-  $\beta$ -strands, two  $\beta$ -sheets**.....

13a. **N**-terminus amino acid is Leu727.... and **C**-terminus amino acid is Arg983.....

How meny amino acids have MR polypeptide 984.... (see 2<sup>nd</sup> page) and **2AA2.pdb** molecule

$$983-727+1=256+1=257 \dots ?$$

2AA2, Aldosterone

2AA7, Deoxycorticosterone

2AA5, Progesterone

2AA6, Progesterone, mutant S810L

2AAX, Cortisone, mutant

2AB2, Spironolactone, mutant

3VHU, deoxycorticosterone, 2011J.Med.Chem. 54: 8616-8631

**13b.** **N-terminus** amino acid is Ser600.....and **C-terminus** amino acid is Arg671.....! How many amino acids have MR polypeptide 984.... (see 2<sup>nd</sup> page) and **4TNT.pdb** **671-600+1=72**.....

>2AA2; 4TNT | P08235 | MCR\_HUMAN receptor OS=Homo sapiens 984 AA  
1 60  
METKGYHSLPEGLDMERRWGQVSQAVERSSLGPTERTDENNYMEIVNVSCVSGAIPNNST  
61 120  
QGSSKEKQELLPCQLQQDNNRPGILTS DIKTELESKELSATVAESMGLYMDSVRDADYSYE  
121 180 DNS  
QQNQQGSMSPAKIYQNVEQLVKFYKGNGHRPSTLSCVNTPRLRSFMSDGS SVNGGVMRAV  
181 2400 DNS  
VKSPIMCHEKSPSVCSPLNM TSSVCSPAGINSVSSTASFGSF PVHSPITQGTPLTCSPN  
241 300  
VENRGSRSHSPA HASNVGSP LSSPLSSMKSSISSPPSHCSVKSPVSSPNNVTLRSSVSSP  
301 360  
ANINNSRCVSSPSNTNNRSTLSSPAASTVGSI CSPVNAFSYTASG TSAGSSTLRDVVP  
361 420  
SPDTQEKG AQEVPFPKTEEVE SAISNGVTGQLNIVQYIKPEPDGAFSSCLGGNSKINSD  
421 480  
SSFSVPIKQESTKHCSGT SFKGNPTVNPFPMDGSYFSFMDDKDYYLSGILGPPVPGF  
481 540  
DGNCEGSGFPVGIKQE PDDGSYYPEASIPSSAIVGVNSGGQSFHYRIGAQGTISLSRSAR  
541 600  
DQS FQHLSSFPPVNTLVE SWKSHGDLSSRRSDGYPVLEYI PENVSSSTLRSVSTGSSRPS  
601 660  
KICLVCGDEASGCHYGVVTCGSKVFFKRAVEQHNYLCAGRNDI IDKIRRKNC PACRL 4TNT . PDB  
661 720  
OKCLQAGMNLG ARKSKKLGKLKG IHEEQPQQQQPPPPPPQSPEEGTTIAPAKEPSVN DNA  
721 780  
TALVPQLSTISRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQV  
781 840  
VKWAKVLPGFKNLPLEDQITLIQYSWMCLSSFALSWR SYKHTNSQFLYFAPDLVFNEEK 2AA2 . PDB  
841 900 Aldosterone  
HQSAM YELCQGMHQISLQFVRLQLTFEEYTIMKVLLLSTIPKDGLKSQAAFEEMRTNYI  
901 960  
KELRK MVTKCPNNSGQSWQRFYQLTKLLDSMHD LVSDLLEFCFYTFRESHALKVEFPAML  
961 970 980 984 1020  
VEIIISDQLPKVESGNAKPLYFHRK

14. What difference has **Hydrocortisone (HCY)** relative to Aldosterone?

..... instead aldehyde C13  $\text{O}=\text{CH}-$  is methyl group  $-\text{CH}_3$  and C17 instead C-H is C- $\text{OH}$ .....


15. Put in **Hydrocortisone (HCY)** hydrocarbon MW=358.44 g/mol

chains C21 structural formula having two carbonyl

$\text{O}=\text{C}<$  and three hydroxyl oxygen atoms  $-\text{OH}$ !

Show carbon  $-\text{C}-$  cyclic structures **A,B,C,D**

double bond  $>\text{C}=\text{C}<$  and two methyl groups  $-\text{CH}_3$ !



16. What two water molecules with hydrogen bonds stabilize **Aldosterone** binding in **LBD**?

.....  $\text{HOH26}, \text{HOH5}$  .....

17. What three amino acids bind with hydrogen bonds hydroxyl group  $-\text{O}-\text{H}$  of **aldosterone**?

.....Phe941,Cys942,Thr945 .....

18. What four amino acids bind with hydrogen bonds carbonyl group  $\text{O}=\text{C}<$  of **aldosterone**?

.....Arg817,Ser810,Phe829,Gln776 .....

19. What fifteen amino acids make **active** of **MR** by hydrophilic & hydrophobic pocket for **aldosterone** complementary connection of **receptor** with **AF-2 Helix** and **loop H3**?

Ser767.....,Asn770.....,Ala773.....,Gln776.....,Phe829.....,Ser810.....,Arg817.....,

Met852.....,Leu938.....,Met807.....,Phe941.....,Cys942.....,Thr945.....,Phe956.....,Glu955.....

20. What difference has **Cortisone** relative to Aldosterone? instead  $\text{O}=\text{CH}-$  methyl group  $-\text{CH}_3$ ....., double bonds C1=C2.....,C20=C21..... and C11 C=O..... .

21. Put in **Cortisone**

hydrocarbon chains C21

structural formula two

carbonyl  $\text{O}=\text{C}<$  and three


hydroxyl oxygen atoms  $-\text{OH}$ !

at C4=C5, C1=C2 and

C20=C21 and two methyl

groups  $-\text{CH}_3$ !

MW=358.44 g/mol




Show carbon  $-\text{C}-$  cyclic structures **A,B,C,D**, double bond  $>\text{C}=\text{C}<$

20. What two amino acids make disulfide bond in **LBD** protein unit structure 1E3G.pdb?

..... disulfide bond Cys669.....- **S - S** -Cys 844 .....

**21.** What difference has **Progesterone** relative to Aldosterone? instead **O=CH-** is methyl group **-CH<sub>3</sub>**...., at C20 carbonyl group >**C=O**.... no hydroxyls **-OH** at C11...,C17...,C21.... .


**22. Put in Progesterone STR**  
hydrocarbon chains C21  
structural formula two carbonyl **O=C<** and no one hydroxyl oxygen atoms **-OH!**



Show carbon –C– cyclic structures **A,B,C,D**, double bond >**C=C<** at C4=C5 and two methyl groups **-CH<sub>3</sub>!**


**23.** Show difference **Desoxycorticosterone** to Aldosterone? instead **O=CH-** methyl **-CH<sub>3</sub>**... at C20 carbonyl >**C=O**... at C21 hydroxyl acetate ester... no hydroxyl **-OH** at C11...,C17.... .

**24. Put in Desoxycorticosterone**  
**DOC** hydrocarbon chains C23  
structural formula two carbonyl **O=C<** and no hydroxyl oxygen **-OH** C11,C17. Show carbon –C– cyclic structures **A,B,C,D**, double bond >**C=C<** at C4=C5 and two methyl groups **-CH<sub>3</sub>!**



**25.** Show difference **Spironolactone SNL** to Aldosterone? instead C13 aldehyde **O=CH-** methyl group **-CH<sub>3</sub>**...., carboxylate at C22 >**COO-**.... and at C7 sulfur **S**.... .

**26. Put in Spironolactone SNL**  
hydrocarbon chains C22  
structural formula two carbonyl **O=C<** and no one hydroxyl oxygen **-OH!** Show carbon –C– cyclic structures **A,B,C,D**, double bond >**C=C<** at C4=C5 and two methyl groups **-CH<sub>3</sub>!**



**Antagonism of MR and MR—Spironolactone** is an **antihypertensive** that has been used clinically for several decades. The crystal structures of **MR C808S/S810L** with **spironolactone** and **progesterone** provide insights into the requirements needed for **receptor activation** and also provide insights into the molecular basis of **MR modulation**. **MR antagonism** by **progesterone** and **spironolactone** is a “**passive**” **antagonism**. These ligands bind and prevent **MR** from adopting the active conformation by failing to mediate **hydrogen bonding** to **Asn770** and **Thr945**. The result is that both **helix 3** and the **AF-2 helix** are not arranged in the proper position to allow efficient binding of **co activators** Activation Domain (**AD**) of transcription.

**CONCLUSION** We have shown that maximum **MR activation** occurs only when there is simultaneous stabilization of the **loop** preceding the **AF-2 helix** and a strong interaction of the ligand (**aldosterone**) with **helix 10**. Stabilization of the **loop** preceding the **AF-2** requires **hydrogen bonds** between **Asn770** and **Ser767** on **helix 3** and **Glu955** present on this **loop**. Ligands that promote this **hydrogen bond** network and interact with **helix 10** via **hydrogen bonds** or **hydrophobic interaction** with **Thr945** induce a stabilization of **helix 3** and a movement of the **AF-2**, enabling **co activator recruitment** and ultimately gene transcription. This Series of **ligand-mediated activation** steps ensures that **ligands** such as **progesterone** and **cortisone** fail to activate **MR** even though these **ligands** will be in excess over **aldosterone** in many tissues. Likewise, **spironolactone** also fails to activate **MR** because of an inability to create the **hydrogen bonding** network as **hydrogen bonding MR antagonist**.